Maria Mancini - Champions Oncology Chief Operations
| CSBR Stock | USD 4.62 0.15 3.14% |
Insider
Maria Mancini is Chief Operations of Champions Oncology
| Address | One University Plaza, Hackensack, NJ, United States, 07601 |
| Phone | 201 808 8400 |
| Web | https://www.championsoncology.com |
Champions Oncology Management Efficiency
The company has return on total asset (ROA) of (0.1748) % which means that it has lost $0.1748 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8865) %, meaning that it created substantial loss on money invested by shareholders. Champions Oncology's management efficiency ratios could be used to measure how well Champions Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/05/2024, Return On Tangible Assets is likely to drop to -0.15. In addition to that, Return On Capital Employed is likely to drop to -0.33. At this time, Champions Oncology's Total Assets are relatively stable compared to the past year. As of 06/05/2024, Non Current Assets Total is likely to grow to about 17.9 M, while Intangible Assets are likely to drop slightly above 650.6 K.Similar Executives
| Found 6 records | INSIDER Age | ||
| Gerald Goodman | Nutriband | 76 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| Eddie Sullivan | SAB Biotherapeutics | 57 | |
| Christine MBA | SAB Biotherapeutics | 68 | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Jeffrey PharmD | Nutriband | 54 | |
Management Performance
| Return On Equity | -3.89 | ||||
| Return On Asset | -0.17 |
Champions Oncology Leadership Team
Elected by the shareholders, the Champions Oncology's board of directors comprises two types of representatives: Champions Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Champions. The board's role is to monitor Champions Oncology's management team and ensure that shareholders' interests are well served. Champions Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Champions Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marianna Zipeto, Research Commercial | ||
| Michael MBA, Chief Officer | ||
| Maria Mancini, Chief Operations | ||
| Karin Heidemann, Executive Operations | ||
| Ronnie MD, CEO Director | ||
| Arthur Hanson, Vice Technology | ||
| BS CMAR, Ex Operations | ||
| David MBA, Chief Officer | ||
| Brady Davis, President | ||
| MBA MS, VP Marketing |
Champions Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Champions Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.89 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 66.01 M | ||||
| Shares Outstanding | 13.59 M | ||||
| Shares Owned By Insiders | 25.55 % | ||||
| Shares Owned By Institutions | 42.30 % | ||||
| Number Of Shares Shorted | 56.11 K | ||||
| Price To Earning | 220.00 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.